Pharmacometrics

Chair

Anders Åsberg
Oslo, Norway

Vice-Chair

Iris Minichmayr
Vienna, Austria

Committee Purpose

  • To advance the field of ‘model-informed personalised dosing’ and its application in the clinical setting across different therapeutic areas.
  • To improve the design of clinical trials based on pharmacometric models using optimised study designs.
  • To develop and share educational tools on clinical pharmacometrics.
  • To carry out collaborative activities with other committees of the IATDMCT.
  • To actively participate in joint meetings with other societies.

Pharmacometrics (PMx) has emerged as a key discipline in the drug development process and is steadily gaining importance in clinical study design and patient care. It encompasses the development of diverse models, including PK-PD (pharmacokinetic-pharmacodynamic), PK-PD-PG (pharmacokinetic-pharmacodynamic-pharmacogenetic), PBPK (physiology-based pharmacokinetic), or ML (machine learning) models.
 
PMx models can help to describe and predict drug concentrations, their relationship with drug effects and clinical outcomes, and provide knowledge about the behaviour of a drug and its optimal usage. The application of PMx models, facilitated by sophisticated software tools, can greatly aid in dose adjustments tailored to a patient’s individual characteristics available in the clinical setting. For example, PMx plays an increasingly crucial role in guiding dosing decisions within the framework of therapeutic drug monitoring. Additionally, PMx can offer insights into the necessary number of participants and the optimal timing of sample collection in clinical studies.

2024

PMx Committee-endorsed webinar ‘International Perspectives on Model-Informed Precision Dosing: From the Data to the Patients’ (March 21, 2024; hosted by Simulations Plus).
 

2023

Pharmacometrics and machine learning symposium at the IATDMCT meeting in Oslo.
 

2023

Joint symposium with the Immunosuppressive Drugs Committee at the IATDMCT meeting in Prague;
Pre-congress symposium ‘Model-informed precision dosing’ at the IATDMCT meeting in Prague.
 

2021

The PMx Committee organised the pre-congress symposium of the IATDMCT congress in Rome. This meeting was aimed at individuals who were not routinely engaged in PK/PD modelling.

Roundtable session at the IATDMCT meeting in Rome: ‘The Use of Machine Learning Approaches in Clinical Pharmacology’.

2024

Contribution to the IATDMCT Position Statement on Best Practice for Infliximab Therapeutic Drug Monitoring:
Alsoud D, Moes DJAR, Wang Z, Soenen R, Layegh Z, Barclay M, Mizuno T, Minichmayr IK, Keizer RJ, Wicha SG, Wolbink G, Lambert J, Vermeire S, de Vries A, Papamichael K, Padullés-Zamora N, Dreesen E. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2024 Jun 1;46(3):291-308. doi: 10.1097/FTD.0000000000001204. Epub 2024 Apr 17. PMID: 38648666.
 

2023

Compass submissions:

  • Model-informed precision dosing to enhance therapeutic drug monitoring (issue March 2023)

 

2022

Compass submissions:

  • Development of a machine learning algorithm to estimate the inter-dose AUC based on simulations obtained with a population pharmacokinetic model: The example of tacrolimus (issue March 2022)

 

2021

Compass submissions:

  • Model-based starting dose for tacrolimus in adult kidney transplant recipients, novel pharmacokinetic applications, and an invitation to learn about these approaches at the Congress in Rome (issue September 2021)
  • Application of machine learning to estimate the immunosuppressant exposure: toward a new way to perform therapeutic drug monitoring (issue March 2021)

2020

Compass submissions:

  • Report from Pmetrics and BestDose workshop in Argentina (issue March 2020).
  • The use of pharmacometrics in COVID-19 patients (issue September 2020).

2019

Compass submissions:

  • Dosing algorithms of tacrolimus in children (issue September 2019).